Abdel Hmissi
About
Abdel Hmissi is a scholar working on Genetics, Hematology and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Abdel Hmissi has authored 34 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 16 papers in Hematology and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Abdel Hmissi's work include Hemoglobinopathies and Related Disorders (15 papers), Iron Metabolism and Disorders (11 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Abdel Hmissi is often cited by papers focused on Hemoglobinopathies and Related Disorders (15 papers), Iron Metabolism and Disorders (11 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Abdel Hmissi collaborates with scholars based in Switzerland, United States and United Kingdom. Abdel Hmissi's co-authors include Aimery de Gramont, Filippo de Braud, F. Morvan, Christophe Louvet, N Le Bail, D. Papamichael, C. Boni, Daniel Hendler, Andrea Bonetti and Jim Cassidy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.
In The Last Decade
Abdel Hmissi
34 papers receiving 4.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Abdel Hmissi Switzerland | 17 | 2.7k | 902 | 901 | 900 | 549 | 34 | 4.1k | ||
| Mohamed Hebbar France | 37 | 2.0k 0.7× | 1.1k 1.2× | 672 0.7× | 761 0.8× | 1.2k 2.2× | 151 | 4.6k | ||
| Ralph Levitt United States | 27 | 2.1k 0.8× | 479 0.5× | 682 0.8× | 892 1.0× | 670 1.2× | 67 | 3.6k | ||
| Vincenzo Catalano Italy | 40 | 3.1k 1.2× | 667 0.7× | 1.2k 1.3× | 1.6k 1.8× | 1.4k 2.5× | 124 | 5.1k | ||
| D. Machover France | 22 | 1.5k 0.5× | 299 0.3× | 335 0.4× | 616 0.7× | 436 0.8× | 85 | 2.3k | ||
| J. L. Misset France | 27 | 2.1k 0.8× | 419 0.5× | 452 0.5× | 1.0k 1.2× | 433 0.8× | 63 | 3.0k | ||
| Muhammad Wasif Saif United States | 25 | 1.7k 0.6× | 180 0.2× | 475 0.5× | 639 0.7× | 562 1.0× | 129 | 2.7k | ||
| Dong Bok Shin South Korea | 28 | 2.4k 0.9× | 245 0.3× | 1.4k 1.6× | 2.5k 2.7× | 504 0.9× | 112 | 4.2k | ||
| David Walde Canada | 16 | 3.7k 1.4× | 303 0.3× | 901 1.0× | 1.4k 1.6× | 1.0k 1.9× | 22 | 4.8k | ||
| Roberto Buzzoni Italy | 33 | 2.5k 0.9× | 197 0.2× | 474 0.5× | 678 0.8× | 459 0.8× | 165 | 3.7k | ||
| John Hamm United States | 22 | 4.0k 1.5× | 329 0.4× | 624 0.7× | 1.6k 1.8× | 1.1k 2.0× | 74 | 5.2k |
Countries citing papers authored by Abdel Hmissi
Since
Specialization
Citations
This map shows the geographic impact of Abdel Hmissi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abdel Hmissi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abdel Hmissi more than expected).
Fields of papers citing papers by Abdel Hmissi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Abdel Hmissi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abdel Hmissi. The network helps show where Abdel Hmissi may publish in the future.
Co-authorship network of co-authors of Abdel Hmissi
This figure shows the co-authorship network connecting the top 25 collaborators of Abdel Hmissi. A scholar is included among the top collaborators of Abdel Hmissi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abdel Hmissi. Abdel Hmissi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sinnaeve, Peter, Gregor Fahrni, Alessandro Spirito, et al.. (2020). Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology. 75(20). 2588–2597.
2.
Storey, Robert F., Paul A. Gurbel, Jurriën M. ten Berg, et al.. (2019). Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. European Heart Journal. 41(33). 3132–3140.
3.
Higashida, Randall T., Nicolas Bruder, Raphaël Guzman, et al.. (2019). Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study. World Neurosurgery. 128. e639–e648.
4.
Mayer, Stephan A., E. François Aldrich, Nicolas Bruder, et al.. (2019). Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage. Stroke. 50(10). 2738–2744.
5.
Sinnaeve, Peter, Gregor Fahrni, Alessandro Spirito, et al.. (2019). 5232Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: a randomised open-label phase 2 study. European Heart Journal. 40(Supplement_1).
6.
Ratner, Paul H., Charles P. Andrews, Frank C. Hampel, et al.. (2017). Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies. Allergy Asthma and Clinical Immunology. 13(1). 18–18.
7.
Black, Jed, Giora Pillar, Jan Hedner, et al.. (2017). Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference. Sleep Medicine. 36. 86–94.
8.
Vannucchi, Alessandro M., H. Kantarjian, Jean‐Jacques Kiladjian, et al.. (2015). A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 100(9). 1139–1145.
9.
Pascoe, Steven, Christine Reynolds, Warren Pleskow, et al.. (2011). Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. International Journal of Clinical Pharmacology and Therapeutics. 49(2). 153–161.
10.
Beier, Jutta, Kai Michael Beeh, L Brookman, et al.. (2009). Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulmonary Pharmacology & Therapeutics. 22(6). 492–496.
11.
Taher, Alì, Amal El‐Beshlawy, Mohsen Saleh Elalfy, et al.. (2009). Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia: the ESCALATOR study. European Journal Of Haematology. 82(6). 458–465.
12.
Lee, Jong Wook, Sung‐Soo Yoon, Hui‐Chi Hsu, et al.. (2008). Iron Chelation in Regularly Transfused Patients with Aplastic Anemia: Efficacy and Safety Results from the Large Deferasirox EPIC Trial. Blood. 112(11). 439–439.
13.
Porter, John B., Gian Luca Forni, Photis Beris, et al.. (2008). Efficacy and Safety of 1 Year’s Treatment with Deferasirox (Exjade®): Assessment of Regularly Transfused Patients with Diamond-Blackfan Anemia Enrolled in the EPIC Study.. Blood. 112(11). 1048–1048.
14.
Gattermann, Norbert, Mathias Schmid, Matteo Giovanni Della Porta, et al.. (2008). Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial. Blood. 112(11). 633–633.
15.
Daar, Shahina, Anil Pathare, Hanspeter Nick, et al.. (2008). Reduction in labile plasma iron during treatment with deferasirox, a once‐daily oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia. European Journal Of Haematology. 82(6). 454–457.
16.
Cappellini, Maria Domenica, Mohsen Saleh Elalfy, Antonis Kattamis, et al.. (2008). Efficacy and Safety of Once-Daily, Oral Iron Chelator Deferasirox (Exjade®) in a Large Group of Regularly Transfused Patients with β-Thalassemia Major. Blood. 112(11). 3878–3878.
17.
Tedesco‐Silva, Hélio, Péter Szakály, Ahmed Shoker, et al.. (2007). FTY720 Versus Mycophenolate Mofetil in De Novo Renal Transplantation: Six-Month Results of a Double-Blind Study. Transplantation. 84(7). 885–892.
18.
Salvadori, Maurizio, Klemens Budde, B Charpentier, et al.. (2006). FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia. American Journal of Transplantation. 6(12). 2912–2921.
19.
Snell, G., Vincent G. Valentine, Patrizio Vitulo, et al.. (2005). Everolimus Versus Azathioprine in Maintenance Lung Transplant Recipients: An International, Randomized, Double-Blind Clinical Trial. American Journal of Transplantation. 6(1). 169–177.
20.
Gramont, Aimery de, Arié Figer, Michel Seymour, et al.. (2000). Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology. 18(16). 2938–2947.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mohamed Hebbar Breakdown of academic impact, for papers by Ralph Levitt Breakdown of academic impact, for papers by Vincenzo Catalano Breakdown of academic impact, for papers by D. Machover Breakdown of academic impact, for papers by J. L. Misset Breakdown of academic impact, for papers by Muhammad Wasif Saif Breakdown of academic impact, for papers by Dong Bok Shin Breakdown of academic impact, for papers by David Walde Breakdown of academic impact, for papers by Roberto Buzzoni Breakdown of academic impact, for papers by John Hamm